- Home
- GALT
GALT
Galectin Therapeutics Inc.
as 04-18-2025 1:36pm EST
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | NORCROSS |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 298.9K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.76 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.73 - $3.78 | Next Earning Date: | 05-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Galectin Therapeutics Inc. News
GALT Breaking Stock News: Dive into GALT Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 Congress
Zacks
12 days ago
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
GlobeNewswire
19 days ago
Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update
Simply Wall St.
a month ago
While insiders own 20% of Galectin Therapeutics Inc. (NASDAQ:GALT), individual investors are its largest shareholders with 54% ownership
GlobeNewswire
2 months ago
Galectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial
Argus Research
3 months ago
Daily – Vickers Top Insider Picks for 01/17/2025
Argus Research
3 months ago
Daily – Vickers Top Insider Picks for 01/16/2025
Argus Research
3 months ago
Daily – Vickers Top Insider Picks for 01/15/2025
Compare GALT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GALT Galectin Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.